152

BIBLIOGRAPHY

1. Aires KA, Cianciarullo AM, Carneiro SM, Villa LL, Boccardo E,

Perez-Martinez G. Production of human papillomavirus type 16 L1

virus-like particles by recombinant Lactobacillus casei cells. Appl.

Environ. Microbiol. 72, 2006: 745–752.

2. Al Saleh, W., Giannini, S.L., Jacobs, N., Moutschen, M., Doyen, J.,

Boniver, J., and Delvenne, P. Correlation of T-helper secretory

differentiation and types of antigen-presenting cells in squamous

intraepithelial lesions of the uterine cervix. J Pathol. 184, 1998:

283–290.

3. Alexander, M., Salgaller, M. L., Celis, E., Sette, A., Barnes, W. A.,

Rosenberg, S. A., and Steller, M. A. Generation of tumor-specific

cytolytic T lymphocytes from peripheral blood of cervical cancer

patients by in vitro stimulation with a synthetic human

papillomavirus type 16 E7 epitope. Am J Obstet Gynecol. 175,

1996: 1586-1593.

4. Amin, A.A., Titolo, S., Pelletier, A., Fink, D., Cordingley, M.G. &

Archambault, J. Identification of domains of the HPV11 E1 protein

required for DNA replication in vitro. Virology. 272, 2000: 137–150.

153

5. Amtmann E, Müller H, Sauer G. Equine connective tissue tumors

contain unintegrated bovine papilloma virus DNA. J Virol. 35,

1980: 962-964.

6. Apple, R.J., Erlich, H.A., Klitz, W., Manos, M.M., Becker, T.M., and

Wheeler, C.M. HLA DR-DQ associations with cervical carcinoma

show papillomavirus-type specificity. Nat Genet. 6, 1994: 157–162.

7. Apt D, Watts RM, Suske G, Bernard HU. High Sp1/Sp3 ratios in

epithelial cells during epithelial differentiation and cellular

transformation correlate with the activation of the HPV-16

promoter. Virology. 224, 1996: 281-91.

8. Arany, I., Rady, P., and Tyring, S.K. Alterations in

cytokine/antioncogene expression in skin lesions caused by “low-

risk” types of human papillomaviruses. Viral Immunol. 6, 1993:

255–265.

9. Arbyn M, Dillner J. Review of current knowledge on HPV

vaccination: An Appendix to the European Guidelines for Quality

Assurance in Cervical Cancer Screening. J. Clin. Viro. 38, 2007:

189–197.

154

10. Ault KA Effect of prophylactic human papillomavirus L1 virus-like-

particle vaccine on risk of cervical intraepithelial neoplasia grade 2,

grade 3, and adenocarcinoma in situ: a combined analysis of four

randomized clinical trials. Lancet. 369, 2007: 1861–1868.

11. Baker, T.S., Newcomb, W.W., Olson, N.H., Cowsert, L.M., Olson,

C., and Brown, J.C. Structures of bovine and human

papillomaviruses: analysis by cryoelectron microscopy and three-

dimensional image reconstruction. Biophys J. 60, 1991: 1445–

1456.

12. Band, V., Zajchowski, D., Kulesa, V. & Sager, R. Human papilloma

virus DNAs immortalize normal human mammary epithelial cells

and reduce their growth factor requirements. Proc natl Acad Sci USA.

87, 1990: 463–467.

13. Banks, L., Matlashewski, G., Pim, D., Churcher, M., Roberts, C.,

and Crawford, L. Expression of human papillomavirus type 6 and

type 16 capsid proteins in bacteria and their antigenic

characterization. J Gen Virol. 68, 1987: 3081-3089.

14. Basu P, Chowdhury D. Cervical cancer screening& HPV

vaccination: a comprehensive approach to cervical cancer control.

Ind J Med Res. 130, 2009: 241-246.

155

15. Baud, D., Ponci, F., Bobst, M., De Grandi, P., and Nardelli-

Haefliger, D. Improved efficiency of a Salmonella-based vaccine

against human papillomavirus type 16 virus-like particles achieved

by using a codon-optimized version of L1. J Virol. 78, 2004: 12901–

12909.

16. Bazan SB, de Alencar Muniz Chaves A, Aires KA, Cianciarullo AM,

Garcea RL, Ho PL. Expression and characterization of HPV-16 L1

capsid protein in Pichia pastoris. Arch Virol. 154, 2009: 1609-1617.

17. Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, de

Villiers EM. Classification of papillomaviruses (PVs) based on 189

PV types and proposal of taxonomic amendments. Virology. 401,

2010: 70–79.

18. Bharadwaja M, Hussain S, Nasare V, Das BC. HPV & HPV

vaccination: Issues in developing countries. Ind J Med Res. 130,

2009: 327-333.

19. Bimelt S, Sonnewald U, Galmbachar P, Willmitzer L, Muller M.

Production of human papillomaviruses type 16 virus-like particles

in transgenic plants. J Virol . 77, 2003: 9211-9220.

156

20. Borzacchiello, G., Ambrosio, V., Roperto, S., Poggiali, F.,

Tsirimonakis, E., Venuti, A., Campo, M.S. & Roperto, F. Bovine

papillomavirus type 4 in oesophageal papillomas of cattle from the

south of Italy. J comp Pathol. 128, 2003b: 203–206.

21. Borzacchiello G, Russo V, Spoleto C, Roperto S, Balcos L, Rizzo C,

Venuti A, Roperto F. Bovine papillomavirus type-2 DNA and

expression of E5 and E7 oncoproteins in vascular tumours of the

urinary bladder in cattle. Cancer Lett. 18; 250, 2007: 82-91.

22. Bosch, F.X., Manos, M.M., Munoz, N., Sherman, M., Jansen, A.M.,

Peto, J., Schiffman, M.H.,Moreno, V., Kurman, R. & Shah, K.V. for

the International Biological Study on Cervical Cancer (IBSCC) Study

Group Prevalence of human papillomavirus in cervical cancer: A

worldwide perspective. J. natl Cancer Inst. 87, 1995: 796–802.

23. Bosch FX, Munoz N: The viral etiology of cervical cancer. Virus Res.

89, 2002:183-190.

24. Bosch, F. X., Lorincz, A., Munoz, N., Meijer, C. J., and Shah, K. V.

The causal relation between human papillomavirus and cervical

cancer. J Clin Pathol. 55, 2002: 244-265.

157

25. Bosch FX. Epidemiology of human papillomavirus infections: new

options for cervical cancer prevention. Salud Publica Mex. 45 (Suppl

3), 2003: S326-39.

26. Bosch FX, de Sanjosé S. Human papillomavirus and cervical

cancer--burden and assessment of causality. J Natl Cancer Inst

Monogr. 31, 2003: 3-13.

27. Boshart, M., Gissmann, L., Ikenberg, H., Kleinheinz, A., Scheurlen,

W., and zur, H. H. A new type of papillomavirus DNA, its presence

in genital cancer biopsies and in cell lines derived from cervical

cancer. EMBO J. 3, 1984: 1151-1157.

28. Boursnell, M. E., Rutherford, E., Hickling, J. K., Rollinson, E. A.,

Munro, A. J., Rolley, N., McLean, C. S., Borysiewicz, L. K., Vousden,

K., and Inglis, S. C. Construction and characterisation of a

recombinant vaccinia virus expressing human papillomavirus

proteins for immunotherapy of cervical cancer. Vaccine 14, 1996:

1485-1494.

29. Bouvard, V., Matlashewski, G., Gu, Z.-M., Storey, A. & Banks, L.

The human papillomavirus type 16 E5 gene cooperates with the E7

gene to stimulate proliferation of primary cells and increases viral

gene expression. Virology, 203, 1994b: 73–80.

158

30. Breitburd, F., Kirnbauer, R., Hubbert, N.L., Nonnenmacher, B.,

Trin-Dinh- Desmarquet, C., Orth, G., Schiller, J.T., and Lowy, D.R.

Immunization with virus-like particles from cottontail rabbit

papillomavirus (CRPV) can protect against experimental CRPV

infection. J Virol. 69, 1995: 3959–3963.

31. Broker, T.R., and Botchan, M.Papillomaviruses: Retrospectives and

prospectives. Cancer Cells. 4, 1986: 17–36.

32. Burchell AN, Winer RL, de Sanjosé S, Franco EL. Epidemiology and

transmission dynamics of genital HPV infection. Vaccine. 24 Suppl

3:S3, 2006: 52-61.

33. Buck CB, Pastrana DV, Lowy DR, Schiller JT. Generation of HPV

pseudovirions using transfection and their use in neutralization

assays. Methods Mol Med. 119, 2005: 445-462.

34. Burd EM. Human papillomavirus and cervical cancer. Clin

Microbiol Rev. 16, 2003: 1-17.

35. Campo, M.S., Moar, M.H., Jarrett, W.F.H. & Laird, H.M.A new

papillomavirus associated with alimentary cancer in cattle. Nature.

286, 1980: 180–182.

159

36. Campo, M.S. Animal models of papillomavirus pathogenesis. Virus

Res. 89, 2002: 249–261.

37. Carroll, M. W. and Moss, B. Poxviruses as expression vectors. Curr

Opin Biotechnol. 8, 1997: 573-577.

38. Carstens CP.Use of tRNA-supplemented host strains for expression

of heterologous genes in E. coli. Methods Mol Biol. 205, 2003: 225–

233.

39. Carter, J. J., Koutsky, L. A., Hughes, J. P., Lee, S. K., Kuypers, J.,

Kiviat, N., and Galloway, D. A. Comparison of human

papillomavirus types 16, 18, and 6 capsid antibody responses

following incident infection. J Infect Dis. 181, 2000: 1911-1919.

40. Casini, G.L., Graham, D., Heine, D., Garcea, R.L., and Wu, D.T. In

vitro papillomavirus capsid assembly analyzed by light scattering.

Virology. 325, 2004: 320–327.

41. Chambers MA, Stacey SN, Arrand JR, Stanley MA. Delayed-type

hypersensitivity response to human papillomavirus type 16 E6

protein in a mouse model. J Gen Virol. 75, 1994:165-9.

160

42. Chan, S. Y., Delius, H., Halpern, A. L., and Bernard, H. U. Analysis

of genomic sequencesof 95 papillomavirus types: uniting typing,

phylogeny, and taxonomy. J Virol. 69, 3074-3083.

43. Cheng, S., Schmidt-Grimminger, D.C., Murant, T., Broker, T.R.,

and Chow, L.T. Differentiation-dependent up-regulation of the

human papillomavirus E7 gene reactivates cellular DNA replication

in suprabasal differentiated keratinocytes. Genes Dev. 9, 1995:

2335–2349.

44. Chen, X.S., Garcea, R.L., Goldberg, I., Casini, G. & Harrison, S.C.

Structure of small virus like particles assembled from the L1

protein of human papillomavirus 16. Mol Cell. 5, 2000: 557–567.

45. Chen, X. S., Casini, G., Harrison, S. C., and Garcea, R. L.

Papillomavirus capsid protein expression in Escherichia coli:

purification and assembly of HPV11 and HPV16 L1. J Mol Biol. 307,

2001:173-182.

46. Chiang, C. M., Ustav, M., Stenlund, A., Ho, T. F., Broker, T. R.,

and Chow, L. T. Viral E1 and E2 proteins support replication of

homologous and heterologous papillomaviral origins. Proc Natl Acad

Sci. 89, 1992: 5799-5803.

161

47. Christensen, N. D. and Kreider, J. W. Antibody-mediated

neutralization in vivo of infectious papillomaviruses. J Virol. 64,

1990: 3151-3156.

48. Christensen, N. D., Hopfl, R., DiAngelo, S. L., Cladel, N. M.,

Patrick, S. D., Welsh, P. A., Budgeon, L. R., Reed, C. A., and

Kreider, J. W. Assembled baculovirus-expressed human

papillomavirus type 11 L1 capsid protein virus-like particles are

recognized by neutralizing monoclonal antibodies and induce high

titres of neutralizing antibodies. J Gen Virol. 75, 1994a: 2271-2276.

49. Christensen, N. D., Dillner, J., Eklund, C., Carter, J. J., Wipf, G.

C., Reed, C. A., Cladel, N. M., and Galloway, D. A. Surface

conformational and linear epitopes on HPV-16 and HPV-18 L1

virus-like particles as defined by monoclonal antibodies. Virology.

223, 1996a: 174-184.

50. Christensen, N.D., Cladel, N.M., Reed, C.A. & Han, R. Rabbit oral

papillomavirus complete genome sequence and immunity following

genital infection. Virology. 269, 2000: 451–461.

51. Chu, N. R., Wu, H. B., Wu, T., Boux, L. J., Siegel, M. I., and

Mizzen, L. A. Immunotherapy of a human papillomavirus (HPV) type

16 E7-expressing tumour by administration of fusion protein

162

comprising Mycobacterium bovis bacille Calmette-Guerin (BCG)

hsp65 and HPV16 E7. Clin Exp Immunol. 121, 2000: 216-225.

52. Coleman, N., Birley, H.D., Renton, A.M., Hanna, N.F., Ryait, B.K.,

Byrne, M., Taylor- Robinson, D., and Stanley, M.A. Immunological

events in regressing genital warts. Am J Clin Pathol. 102, 1994:

768–774.

53. Combita, A. L., Touze, A., Bousarghin, L., Christensen, N. D., and

Coursaget, P. Identification of two cross-neutralizing linear epitopes

within the L1 major capsid protein of human papillomaviruses. J

Virol. 76, 2002: 6480-6486.

54. Cook CJ, Joyce GJ, George AH, Schultz DL, Hurni MW, Jansen

UK, Hepler WR, Charlotte IP, Lowe SR, Keller MP, Lehman DE.

Purification of Virus-like Particles of Recombinant Human

papillomavirus Type 11 Major Capsid Protein L1fr`om

Saccharomyces cerevisiae. Prot Expr Pur. 17, 1999: 477–484.

55. Cregg JM, Cereghino JI, Shi J, Higgins DR. Recombinant protein

expression in Pichia pastoris. Mol Biotechnol. 16, 2000: 23-52.

56. Crotty, S., Miller, C. J., Lohman, B. L., Neagu, M. R., Compton, L.,

Lu, D., Lu, F. X., Fritts, L., Lifson, J. D., and Andino, R. Protection

163

against simian immunodeficiency virus vaginal challenge by using

Sabin poliovirus vectors. J Virol. 75, 2001: 7435-7452.

57. Crusius, K., Auvinen, E. & Alonso, A. Enhancement of EGF- and

PMA-mediated MAP kinase activation in cells expressing the human

papillomavirus type 16 E5 protein. Oncogene. 15, 1997: 1437–

1444.

58. Crusius, K., Auvinen, E., Steuer, B., Gaissert, H. & Alonso, A. The

human papillomavirus type 16 E5-protein modulates ligand-

dependent activation of the EGF receptor family in the human

epithelial cell line HaCaT. Exp Cell Res. 241, 1998: 76–83.

59. Cumberbatch, M. and Kimber, I. Dermal tumour necrosis factor-

alpha induces dendritic cell migration to draining lymph nodes, and

possibly provides one stimulus for Langerhans’ cell migration.

Immunology. 75, 1992: 257–263.

60. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G,

Mayrand MH, Dillner J, Meijer CJ. Overview of human

papillomavirus-based and other novel options for cervical cancer

screening in developed and developing countries. Vaccine. 26, Suppl

10, 2008: K29-41.

164

61. Danos, O., Giri, I., Thierry, F., and Yaniv, M. Papillomavirus

genomes: sequences and consequences. J Invest Dermatol. 83,

Suppl 1, 1984: S7–11.

62. Davidson, E. J., Brown, M. D., Burt, D. J., Parish, J. L., Gaston,

K., Kitchener, H. C., Stacey, S. N., and Stern, P. L. Human T cell

responses to HPV 16 E2 generated with monocyte derived dendritic

cells. Int J Cancer. 94, 2001: 807-812.

63. Da Silva, D.M., Pastrana, D.V., Schiller, J.T., and Kast, W.M. Effect

of preexisting neutralizing antibodies on the anti-tumor immune

response induced by chimeric human papillomavirus virus-like

particle vaccines. Virology. 290, 2001: 350–360.

64. Das BC, Hussain S, Nasare V, Bharadwaj M. Prospects and

prejudices of human papillomavirus vaccines in India. Vaccine. 26,

2008: 2669-2679.

65. Day, P. M., Roden, R. B., Lowy, D. R., and Schiller, J. T. The

papillomavirus minor capsid protein, L2, induces localization of the

major capsid protein, L1, and the viral transcription/replication

protein, E2, to PML oncogenic domains. J Virol. 72, 1998: 142-150.

66. De Bruijn, M.L.H., Greenstone, H.L., Vermeulen, H., Melief, C.J.M.,

Lowy, D.R., Schiller, J.T., and Kast, W.M. L1-specific protection

165

from tumor challenge elicited by HPV16 virus-like particles.

Virology. 250, 1998: 371–376.

67. del Mar Pena, L.M., and Laimins, L.A. Differentiation-dependent

chromatin rearrangement coincides with activation of human

papillomavirus type 31 late gene expression. J Virol. 75, 2001:

10005–10013.

68. Deng, S.-J., Pearce, K.H., Dixon, E.P., Hartley, K.A., Stanley, T.B.,

Lobe, D.C., Garvey, E.P., Kost, T.A., Petty, R.L., Rocque, W.J.,

Alexander, K.A. & Underwood, M.R. Identification of peptides that

inhibit the DNA binding, trans-activator, and DNA replication

functions of the human papillomavirus type 11 E2 protein. J Virol.

78, 2004: 2637–2641.

69. De Villier EM, Fauquet C, Broker TR, Bernard HU, zur Hausen

H.Classification of papillomaviruses. Virology. 324, 2004: 17–27

70. Desaintes, C. & Demeret, C. Control of papillomavirus DNA

replication and transcription. Semin Cancer Biol. 7, 1996: 339–347.

71. Desaintes, C., Demeret, C., Goyat, S., Yaniv, M., and Thierry, F.

Expression of the papillomavirus E2 protein in HeLa cells leads to

apoptosis. EMBO J. 16, 1997: 504-514.

166

72. Dillner, J., Lehtinen, M., Bjorge, T., Luostarinen, T., Youngman, L.,

Jellum, E., Koskela, P., Gislefoss, R.E., Hallmans, G., Paavonen, J.,

Sapp, M., Schiller, J.T., Hakulinen, T., Thoresen, S., and Hakama,

M. Prospective seroepidemiologic study of human papillomavirus

infection as a risk factor for invasive cervical cancer. J Natl Cancer

Inst. 89, 1997: 1293–1299.

73. Doorbar, J. The papillomavirus life cycle. J Clin Virol. 32 Suppl 1,

2005: S7–S15.

74. Favre M, Majewski S, De Jesus N, Malejczyk M, Orth G, Jablonska

S. A possible vertical transmission of human papillomavirus

genotypes associated with epidermodysplasia verruciformis. J Invest

Dermatol. 111, 1998: 333-336.

75. Fehrmann, F. & Laimins, L.A. Human papillomaviruses: Targeting

differentiating epithelial cells for malignant transformation.

Oncogene. 22, 2003: 5201–5207.

76. Ferlay, J., Bray, F., Pisani, P., and Parkin, D.M. GLOBOCAN 2002:

Cancer Incidence, Mortality and Prevalence Worldwide. Lyon: IARC

Press, 2004.

77. Fernando, G. J., Murray, B., Zhou, J., and Frazer, I. H.

Expression, purification and immunological characterization of the

167

transforming protein E7, from cervical cancerassociated human

papillomavirus type 16. Clin Exp Immunol. 115, 1999: 397-403.

78. Fernández-San Millán A, Ortigosa SM, Hervás-Stubbs S, Corral-

Martínez P, Seguí-Simarro JM, Gaétan J, Coursaget P, Veramendi

J. Human papillomavirus L1 protein expressed in tobacco

chloroplasts self-assembles into virus-like particles that are highly

immunogenic. Plant Biotechnol J. 6, 2008: 427-441.

79. Flores, E.R., Allen-Hoffmann, B.L., Lee, D., Sattler, C.A., and

Lambert, P.F. Establishment of the human papillomavirus type 16

(HPV-16) life cycle in an immortalized human foreskin keratinocyte

cell line. Virology. 262, 1999: 344–354.

80. Flores, E.R., Allen-Hoffmann, B.L., Lee, D., and Lambert, P.F. The

human papillomavirus type 16 E7 oncogene is required for the

productive stage of the viral life cycle. J Virol. 74, 2000: 6622–6631.

81. Florin, L., Sapp, C., Streeck, R. E., and Sapp, M. Assembly and

Translocation of Papillomavirus Capsid Proteins. J Virol. 76, 2002:

10009-10014.

82. Fisher, S.G., Benitez-Bribiesca, L., Nindl, I., Stockfleth, E., Muller,

M., Wolf, H., Perez-Garcia, F., Guzman-Gaona, J., Gutierrez-

Delgado, F., Irvin, W., and Gissmann, L. The association of human

168

papillomavirus type 16 E6 and E7 antibodies with stage of cervical

cancer. Gynecol Oncol. 61, 1996: 73–78.

83. Franceschi S, Rajkumar T, Vaccarella S, Gajalakshmi V, Sharmila

A, Snijders PJ, et al. Human papillomavirus and risk factors for

cervical cancer in Chennai, in India: a case control study. Int J

Cancer. 107, 2003: 127-133.

84. Frattini, M.G. & Laimins, L.A. Binding of the human

papillomavirus E1 origin-recognition protein is regulated through

complex formation with the E2 enhancer-binding protein. Proc Natl

Acad Sci USA. 91, 1994: 12398–12402.

85. Frattini, M.G., Lim, H.B., and Laimins, L.A. In vitro synthesis of

oncogenic human papillomaviruses requires episomal genomes for

differentiation-dependent late expression. Proc Natl Acad Sci USA.

93, 1996: 3062–3067.

86. Gambhira, R., S. Jagu, B. Karanam, P. E. Gravitt, T. D. Culp, N. D.

Christensen and R. B. S. Roden. Protection of rabbits against

challenge with rabbit papillomaviruses by immunization with the N

terminus of human papillomavirus type 16 minor capsid antigen

L2. J Virol. 81, 2007: 11585–11592.

169

87. Gao, L., Chain, B., Sinclair, C., Crawford, L., Zhou, J., Morris, J.,

Zhu, X., and Stauss, H. Immune response to human papillomavirus

type 16 E6 gene in a live vaccinia vector. J Gen Virol. 75, 1994: 157-

164.

88. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper

DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo

FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C,

Barr E, Koutsky LA; Females United to Unilaterally Reduce

Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent

vaccine against human papillomavirus to prevent anogenital

diseases. N Engl J Med. 356, 2007: 1928-1943.

89. GAVI Alliance Progress Report (GAVI Alliance, Geneva, 2007).

http://www.gavialliance.org/resources/2007GAVIreport.pdf.

90. Giroglou, T., Sapp, M., Lane, C., Fligge, C., Christensen, N. D.,

Streeck, R. E., and Rose, R. C. Immunological analyses of human

papillomavirus capsids. Vaccine. 19, 2001: 1783-1793.

91. Glas, R., Franksson, L., Une, C., Eloranta, M.L., Ohlen, C., Orn,

A., and Karre, K. Recruitment and activation of natural killer (NK)

cells in vivo determined by the target cell phenotype. An adaptive

170

component of NK cell-mediated responses. J Exp Med. 191, 2000:

129–138.

92. Grassmann, K., Rapp, B., Maschek, H., Petry, K.U., and Iftner, T.

Identification of a differentiation-inducible promoter in the E7 open

reading frame of human papillomavirus type 16 (HPV-16) in raft

cultures of a new cell line containing high copy numbers of

episomal HPV-16 DNA. J Virol. 70, 1996: 2339–2349.

93. Gravitt, P.E., Peyton, C.L., Apple, R.J. & Wheeler, C.M. Genotyping

of 27 human papillomavirus types by using L1 consensus PCR

products by a single hybridization, reverse line blot detection

method. J clin Microbiol. 36, 1998: 3020–3027.

94. Greenstone, H. L., Nieland, J. D., de Visser, K. E., De Bruijn, M. L.,

Kirnbauer, R., Roden, R. B., Lowy, D. R., Kast, W. M., and Schiller,

J. T. Chimeric papillomavirus virus-like particles elicit antitumor

immunity against the E7 oncoprotein in an HPV16 tumor model.

Proc Natl Acad Sci. 95, 1998: 1800-1805.

95. Gustafsson C, Govindarajan S, Minshull J . Codon bias and

heterologous protein expression. Trends Biotechnol. 22, 2004: 346–

353.

171

96. Hagenson MJ. Production of recombinant proteins in the

methylotrophic yeast Pichia pastoris. Bioprocess Technol. 12, 1991:

193-212.

97. Hagensee, M. E., Yaegashi, N., and Galloway, D. A. Self-assembly

of human papillomavirus type 1 capsids by expression of the L1

protein alone or by coexpression of the L1 and L2 capsid proteins. J

Virol. 67, 1993: 315-322.

98. Hagensee, M.E., Olson, N.H., Baker, T.S. & Galloway, D.A. Three-

dimensional structure of vaccinia virus-produced human

papillomavirus type 1 capsids. J Virol. 68, 1994: 4503–4505.

99. Halbert, C.L., Demers, G.W., and Galloway, D.A. The E6 and E7

genes of human papillomavirus type 6 have weak immortalizing

activity in human epithelial cells. J Virol. 66, 1992: 2125–2134.

100. Hariharan, K., Braslawsky, G., Barnett, R. S., Berquist, L.

G., Huynh, T., Hanna, N., and Black, A. Tumor regression in mice

following vaccination with human papillomavirus E7 recombinant

protein in PROVAX. Int. J Oncol. 12, 1998: 1229-1235.

101. Harper, D.M., Franco, E.L., Wheeler, C., Ferris, D.G.,

Jenkins, D., Schuind, A., Zahaf, T., Innis, B., Naud, P., De

Carvalho, N.S., Roteli-Martins, C.M., Teixeira, J., Blatter, M.M.,

172

Korn, A.P., Quint, W., Dubin, G., and the GlaxoSmithKline HPV

Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle

vaccine in prevention of infection with human papillomavirus types

16 and 18 in young women: A randomised controlled trial. Lancet.

364, 2004: 1757–1765.

102. Harper, D.M., Tamms, G.M., Yu, J., Lupinacci, L., Railkar, R.,

Taddeo, F.J., Jansen, K.U., Esser, M.T., Sings, H.L., Saah, A.J., and

Barr, E. Prophylactic quadrivalent human papillomavirus (types 6,

11, 16, and 18) L1 virus-like particle vaccine in young women: a

randomized double-blind placebo-controlled multicentre phase II

efficacy trial. Lancet Oncol. 6, 2005: 271–278.

103. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B,

Roteli-Martinus CM, Jenkins D, Schuind A, Clemens SAC, Dubin G.

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle

vaccine against human papillomavirus types 16 and 18: follow up

from a randomized control trial. Lancet. 367, 2006: 1247-1255.

104. Heino, P., Zhou, J. & Lambert, P.F. Interaction of the

papillomavirus transcription/replication factor, E2, and the viral

capsid protein, L2. Virology, 276, 2000: 304–314.

173

105. Hildesheim A, Herrero R, Wacholder S et al. Effect of human

papillomavirus 16/18 L1 viruslike particle vaccine among young

women with preexisting infection: a randomized trial. JAMA. 298,

2007: 743–753.

106. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural

history of cervovaginal papillomavirus infection in young women. N

Engl J Med. 338, 1998: 423-428.

107. Ho, G.Y., Studentsov, Y.Y., Bierman, R., and Burk, R.D. Natural

history of human papillomavirus type 16 virus-like particle

antibodies in young women. Cancer Epidemiol Biomarkers Prev. 13,

2004: 110–116.

108. Holmgren, S.C., Patterson, N.A., Ozbun, M.A. & Lambert, P.F. The

minor capsid protein L2 contributes to two steps in the human

papillomavirus type 31 life cycle. J Virol. 79, 2005: 3938–3948.

109. Howley, P. M. Papillomavirinae: The Viruses and Their Replication.

In "Fields Virology" (B. N. Fields, D. M. Knipe, and P. M. Howley,

Eds.), 1995: 2045-2076.

110. Howley, P.M., Lowy, D.R. Papillomaviruses and their replication. In

P.M. Howley (ed.): Virology, vol. 2. Philadelphia, PA: Lippincott/The

Williams & Wilkins Co. 2001: 2197–2229.

174

111. Hudson, J.B., Bedell, M.A., McCance, D.J., and Laimins, L.A.

Immortalization and altered differentiation of human keratinocytes in

vitro by the E6 and E7 open reading frames of human papillomavirus

type 18. J Virol. 64, 1990: 519–526.

112. Hughes, F.J. & Romanos, M.A. E1 protein of human

papillomavirus is a DNA helicase/ ATPase. Nucleic Acids Res. 21,

1993: 5817–5823.

113. Hummel, M., Hudson, J.B., and Laimins, L.A. Differentiation-

induced and constitutive transcription of human papillomavirus type

31b in cell lines containing viral episomes. J Virol. 66, 1992: 6070–

6080.

114. Hwang, E.-S., Nottoli, T. & DiMaio, D. The HPV16 E5 protein:

Expression, detection, and stable complex formation with

transmembrane proteins in COS cells. Virology. 211, 1995: 227–233.

115. Inglis S, Shaw A, Koenig S. HPV vaccines: commercial research &

development. Vaccine. 24 suppl 3, 2006: S99-S105.

116. Jarrett, W.F.H., Murphy, J., O’Neil, B.W. & Laird, H.M. Virus-

induced papillomas of the alimentary tract of cattle. Int J Cancer. 22,

1978b: 323–328.

175

117. Jarrett, W.F.H. The natural history of bovine papillomavirus

infections. In: Klein, G., ed., Advances in Viral Oncology, Vol. 5, New

York, Raven Press, 1985: 83–102

118. Jenison, S.A., Yu, X.P., Valentine, J.M., Koutsky, L.A.,

Christiansen, A.E., Beckmann, A.M., and Galloway, D.A. Evidence of

prevalent genital-type human papillomavirus infections in adults and

children. J Infect Dis. 162, 1990: 60–69.

119. Kabsch, K. & Alonso, A. The human papillomavirus type 16 E5

protein impairs TRAIL and FasL-mediated apoptosis in HaCaT cells

by different mechanisms. J Virol. 76, 2002: 12162–12172.

120. Kanda, T., Furuno, A., and Yoshiike, K. Humanpapillomavirustype

16 open reading frame E7 encodes a transforming gene for rat 3Y1

cells. J Virol. 62, 1988: 610–613.

121. Kashii, Y., Giorda, R., Herberman, R.B., Whiteside, T.L., and

Vujanovic, N.L. Constitutive expression and role of the TNF family

ligands in apoptotic killing of tumor cells by human NK cells. J

Immunol. 163, 1999: 5358–5366.

176

122. Kawana, K., Yoshikawa, H., Taketani, Y., Yoshiike, K., and Kanda,

T. Common neutralization epitope in minor capsid protein L2 of

human papillomavirus types 16 and 6. J Virol. 73, 1999: 6188-6190.

123. Kawana, Y., Kawana, K., Yoshikawa, H., T aketani, Y., Yoshiike, K.,

and Kanda, T. Human papillomavirus type 16 minor capsid protein

l2 N-terminal region containing a common neutralization epitope

binds to the cell surface and enters the cytoplasm. J Virol. 75, 2001b:

2331-2336.

124. Kawana, K., Yasugi, T., Kanda, T., Kino, N., Oda, K., Okada, S.,

Kawana, Y., Nei, T., Takada, T., Toyoshima, S., Tsuchiya, A., Kondo,

K., Yoshikawa, H., Tsutsumi, O. and Taketani, Y. Safety and

immunogenicity of a peptide containing the cross-neutralization

epitope of HPV16 L2 administered nasally in healthy volunteers.

Vaccine. 21, 2003: 4256–4260

125. Kell, B., Jewers, R. J., Cason, J., Pakarian, F., Kaye, J. N., and

Best, J. M. Detection of E5 oncoprotein in human papillomavirus

type 16-positive cervical scrapes using antibodies raised to synthetic

peptides. J Gen Virol. 75, 1994: 2451-2456.

177

126. Kennedy, I.M., Haddow, J.K. & Clements, J.B. A negative

regulatory element in the human papillomavirus type 16 genome acts

at the level of late mRNA stability. J Virol. 65, 1991: 2093–2097.

127. Kirnbauer, R., Booy, F., Cheng, N., Lowy, D. R., and Schiller, J. T.

Papillomavirus L1 major capsid protein self-assembles into virus-like

particles that are highly immunogenic. Proc Natl Acad Sci. 89, 1992:

12180-12184.

128. Kirnbauer, R., Taub, J., Greenstone, H., Roden, R., Durst, M.,

Gissmann, L., Lowy, D. R., and Schiller, J. T. Efficient self-assembly

of human papillomavirus type 16 L1 and L1-L2 into virus-like

particles. J Virol. 67, 1993: 6929-6936.

129. Knowles G, O'Neil BW, Campo MS. Phenotypical characterization

of lymphocytes infiltrating regressing papillomas. J Virol. 70, 1996:

8451-8.

130. Kochel, H.G., Sievert, K., Monazahian, M., Mittelstadt-Deterding,

A., Teichmann, A., and Thomssen, R. Antibodies to human

papillomavirus type-16 in human sera as revealed by the use of

prokaryotically expressed viral gene products. Virology. 182, 1991b:

644–654.

178

131. Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS.

Persistent human papillomavirus infection and cervical neoplasia: a

systematic review and meta-analyisis. Am J Epideminol. 168, 2008:

123-137.

132. Koutsky, L.A., Ault, K.A., Wheeler, C.M., Brown, D.R., Barr, E.,

Alvarez, F.B., Chiacchierini, L.M., and Jansen, K.U. A controlled trial

of a human papillomavirus type 16 vaccine. N Engl J Med. 347, 2002:

1645–1651.

133. Lacey C J. Therapy for genital human papillomavirus- related

disease. J Clin Virol. 32 Supple 1, 2005: S82-S90.

134. Lai YM, Yang FP, Pao CC. Human papillomavirus deoxyribonucleic

acid and ribonucleic acid in seminal plasma and sperm cells. Fertil

Steril. 65, 1996: 1026-1030.

135. Lambert, P.F. Papillomavirus DNA replication. J Virol. 65, 1991:

3417–3420.

136. Lamikanra, A., Pan, Z. K., Isaacs, S. N., Wu, T. C., and Paterson,

Y. Regression of established human papillomavirus type 16 (HPV-16)

immortalized tumors in vivo by vaccinia viruses expressing different

forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell

responses that home to the tumor site. J Virol. 75, 2001: 9654-9664.

179

137. Leder C, Kleinschmidt JA, Wiethe C, Müller M. Enhancement of

capsid gene expression: preparing the human papillomavirus type 16

major structural gene L1 for DNA vaccination purposes. J Virol.

75(19), 2001: 9201-9.

138. Lenz, P., Day, P.M., Pang, Y.S., Frye, S.A., Jensen, P.N., Lowy,

D.R., and Schiller, J.T. Papillomavirus-like particles induce acute

activation of dendritic cells. J Immunol. 166, 2001: 5346–5355.

139. Lenzi P, Scotti N, Alagna F, Tornesello ML, Pompa A, Vitale A, De

Stradis A, Monti L, Grillo S, Buonaguro FM, Maliga P, Cardi T.

Translational fusion of chloroplast-expressed human papillomavirus

type 16 L1 capsid protein enhances antigen accumulation in

transplastomic tobacco. Transgenic Res. 17, 2008: 1091-102.

140. Li, M., Cripe, T. P., Estes, P. A., Lyon, M. K., Rose, R., and Garcea,

R. L. Expression of the Human Papillomavirus type 11 L1 capsid

protein in Escherichia coli: Characterization of protein domains

involved in DNA binding and capsid assembly. J Virol. 71, 1997:

2988-2995.

141. Liljeqvist, S. and Stahl, S. Production of recombinant subunit

vaccines: protein immunogens, live delivery systems and nucleic acid

vaccines. J Biotechnol. 73, 1999: 1-33.

180

142. Liu, M.A. DNA vaccines: A review. J Intern Med. 253, 2003: 402–

410.

143. Liu DW, Zhang Y, Yu XH, Jiang C, Chen Y, Wu Y, Jin Y. Assembly

and Immunogenicity of Human Papillomavirus Type 16 Major Capsid

Protein (HPV16 L1) in Pichia pastoris. Chem Res in Chinese Univ. 23,

2003: 200-203 (Seen as abstract only).

144. Longworth, M.S., and Laimins, L.A. The binding of histone

deacetylases and the integrity of zinc finger-like motifs of the E7

protein are essential for the life cycleof human papillomavirus type

31. J Virol. 78, 2004a: 3533–3541.

145. Lowy, D. R., Kirnbauer, R., and Schiller, J. T. Genital human

papillomavirus infection. Proc Natl Acad Sci. 91, 1994: 2436-2440.

146. Lowy D. The Papillomaviruses. (Robert L. Garcea, Daniel DiMaio

eds. Springer, 2007: 13-17.

147. Mach H, Volkin DB, Troutman RD, Wang B, Luo Z, Jansen KU, Shi

L. Disassembly and reassembly of yeast-derived recombinant human

papillomavirus virus-like particles (HPV VLPs). J Pharm Sci. 95(10),

2006: 2195-2206.

181

148. Mao C, Hughes JP, Kiviat N, Kuypers J, Lee SK, Adam DE,

Koutsky LA. Clinical findings among young women with genital

human papillomavirus infection. Am J Obstet Gynecol. 188, 2003:

677-684.

149. Martinez-Kinader, B., Lipford, G. B., Wagner, H., and Heeg, K.

Sensitization of MHC class I-restricted T cells to exogenous proteins:

evidence for an alternative class I-restricted antigen presentation

pathway. Immunology. 86, 1995: 287-295.

150. Martin, L.G., Demers, G.W., and Galloway, D.A. Disruption of the

G1/S transition in human papillomavirus type 16 E7-expressing

human cells is associated with altered regulation of cyclin E. J Virol.

72, 1998: 975–985.

151. Martina, B.M., Nina, M., Mia L., Lawrence B. and Helena, S.G.

Modification of Human Papillomavirus Minor Capsid Protein L2 by

Sumoylation. J Virol. 84, 2010: 11585-11589.

152. Mason, H. S., Lam, D. M., and Arntzen, C. J. Expression of

hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci.

89, 1992: 11745-11749.

153. Masterson, P.J., Stanley, M.A., Lewis, A.P. & Romanos, M.A. AC

terminal helicase domain of the human papillomavirus E1 protein

182

binds E2 and the DNA polymerase alpha-primase p68 subunit. J.

Virol. 72, 1998: 7407–7419.

154. McLean CS, Sterling JS, Mowat J, Nash AA, Stanley MA. Delayed-

type hypersensitivity response to the human papillomavirus type 16

E7 protein in a mouse model. J Gen Virol. 74, 1993: 239-245.

155. Meyers, C., Frattini, M.G., Hudson, J.B., and Laimins, L.A.

Biosynthesis of human papillomavirus from a continuous cell line

upon epithelial differentiation. Science. 257, 1992: 971–973.

156. Meyers, C., and Laimins Milich, D. R. Genetic and molecular basis

for T- and B-cell recognition of hepatitis B viral antigens. Immunol

Rev. 99, 1987: 71-103.

157. Moscicki AB, Ellenberg JH, Farhat S, Xu J. Persistence of human

papillomavirus infection in HIV- infected and –uninfected adolescent

girls: risk factors and differences, by phylogenetic type. J Infect Dis.

190, 2004: 37-45.

158. Muller, M., Zhou, J., Reed, T.D., Rittmuller, C., Burger, A.,

Gabelsberger, J., Braspenning, J., and Gissmann, L. Chimeric

papillomavirus-like particles. Virology. 234, 1997: 93–111.

183

159. Muñoz N, Castellsagué X, de González AB, Gissmann L. HPV in

the etiology of human cancer. Vaccine. 24 Suppl 3, 2006: S1-S10.

160. Nakagawa, M., Viscidi, R., Deshmukh, I., Costa, M.D., Palefsky,

J.M., Farhat, S., and Moscicki, A.B. Time course of humoral and cell-

mediated immune responses to human papillomavirus type 16 in

infected women. Clin Diagn Lab Immunol. 9, 2002: 877–882.

161. Nardelli-Haefliger D, Roden RB, Benyacoub J, Sahli R,

Kraehenbuhl JP, Schiller JT, Lachat P, Potts A, De Grandi P. Human

papillomavirus type 16 virus-like particles expressed in attenuated

Salmonella typhimurium elicit mucosal and systemic neutralizing

antibodies in mice. Infect Immun. 65, 1997: 3328-3336.

162. Nardelli-Haefliger, D., Lurati, F., Wirthner, D., Spertini, F.,

Schiller, J.T., Lowy, D.R., Ponci, F., and De Grandi, P. Immune

responses induced by lower airway mucosal immunisation with a

human papillomavirus type 16 virus-like particle vaccine. Vaccine.

23, 2005: 3634–3641.

163. Nasseri, M. & Wettstein, F.O. Differences exist between viral

transcripts in cottontail rabbit papillomavirus-induced benign and

malignant tumors as well as non-virus-producing and virus-

producing tumors. J Virol. 51, 1984: 706–712

184

164. Nelson, L. M., Rose, R. C., and Moroianu, J. Nuclear import

strategies of high risk HPV16 L1 major capsid protein. J Biol Chem.

277, 2002: 23958–23964.

165. Nicholls, P.K., Doorbar, J., Moore, R.A., Peh, W., Anderson, D.M.,

and Stanley, M.A. Detection of viral DNA and E4 protein in basal

keratinocytes of experimental canine oral papillomavirus lesions.

Virology. 284, 2001: 82–98.

166. Nonnenmacher, B., Hubbert, N.L., Kirnbauer, R., Shah, K.V.,

Munoz, N., Bosch, F.X., De Sanjose, S., Viscidi, R., Lowy, D.R., and

Schiller, J.T. Serologic response to human papillomavirus type 16

(HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical

cancer and cervical intraepithelial neoplasia grade III patients and

controls from Colombia and Spain. J Infect Dis. 172, 1995: 19–24.

167. O Connor, M., Chan, S. Y., Bernard, H. U. Transcription factor

binding sites in the long control region of genital HPVs. The Human

Papillomaviruses Compendium On Line (http://hpv-

web.lanl.gov/stdgen/virus/hpv/compendium/htdocs/), 1995: III-21

III-40.

185

168. Oh, S.T., Longworth, M.S., and Laimins, L.A. Roles of the E6 and

E7 proteins in the life cycle of low-risk human papillomavirus type

11. J Virol. 78, 2004b: 2620–2626.

169. Okoye, A., Cordano, P., Taylor, E.R., Morgan, I.M., Everett, R. &

Campo, M.S. Human papillomavirus 16 L2 inhibits the

transcriptional activation function, but not the DNA replication

function, of HPV-16 E2. Virus Res. 108, 2005: 1–14.

170. Okun, M. M., Day, P. M., Greenstone, H. L., Booy, F. P., Lowy, D.

R., Schiller, J. T., and Roden, R. B. L1 interaction domains of

papillomavirus l2 necessary for viral genome encapsidation. J. Virol.

75, 2001: 4332-4342.

171. Padmanabhan S, Amin T, Sampat B, Cook-Deegan R,

Chandrasekharan S. Intellectual property, technology transfer and

manufacture of low-cost HPV vaccines in India. Nat Biotechnol. 28,

2010: 671–678.

172. Paintsil, J., Muller, M., Picken, M., Gissmann, L., and Zhou, J.

Carboxyl terminus of bovine papillomavirus type-1 L1 protein is not

required for capsid formation. Virology. 223, 1996: 238–244.

173. Palker, T.J., Monteiro, J.M., Martin, M.M., Kakareka, C., Smith,

J.F., Cook, J.C., Joyce, J.G., and Jansen, K.U. Antibody, cytokine

186

and cytotoxic T lymphocyte responses in chimpanzees immunized

with human papillomavirus virus-like particles. Vaccine. 19, 2001:

3733–3743.

174. Park, R.B., and Androphy, E.J. Genetic analysis of high-risk e6 in

episomal maintenance of human papillomavirus genomes in primary

human keratinocytes. J Virol. 76, 2002: 11359–11364.

175. Parkin DM, Almonte M, Bruni L, Clifford G, Curado MP, Piñeros M.

Burden and trends of type-specific human papillomavirus infections

and related diseases in the Latin america and Caribbean region.

Vaccine. 26, Suppl 11, 2008: L1-15.

176. Pascoe, R.R., Knottenbelt, D.C.. Manual of equine dermatology.

London WB Saunders. 1999: 244- 250.

177. Pastrana, D.V., Gambhira, R., Buck, C.B., Pang, Y.Y., Thompson,

C.D., Culp, T.D., Christensen, N.D., Lowy, D.R., Schiller, J.T., and

Roden, R.B. Cross neutralization of cutaneous and mucosal

Papillomavirus types with anti-sera to the amino terminus of L2.

Virology. 337, 2005: 365–372.

178. Patel MC, Patkar KK, Basu A, Mohandas KM , Mukhopadhyaya R.

Production of immunogenic human papillomavirus-16 major capsid

187

protein derived virus like particles. Ind J Med Res. 130, 2009: 213-

218.

179. Peacock, J.W., Chung, S., Bristow, R.G., Hill, R.P., and Benchimol,

S. The p53-mediated G(1) checkpoint is retained in tumorigenic rat

embryo fibroblast clones transformed by the human papillomavirus

type 16 E7 gene and EJ-ras. Mol Cell Biol. 15, 1995: 1446–1454.

180. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer

epidemic that screening has prevented in the UK. Lancet. 364, 2006:

249-256.

181. Pim, D., Collins, M., and Banks, L. Human papillomavirus type 16

E5 gene stimulates the transforming activity of the epidermal growth

factor receptor. Oncogene. 7, 1992: 27-32.

182. Plummer, M. and Franceschi, S. Strategies for HPV prevention.

Virus Res. 89, 2002: 285-293.

183. Ressing, M. E., van Driel, W. J., Brandt, R. M., Kenter, G. G., de

Jong, J. H., Bauknecht, T., Fleuren, G. J., Hoogerhout, P., Offringa,

R., Sette, A., Celis, E., Grey, H., Trimbos, B. J., Kast, W. M., and

Melief, C. J. Detection of T helper responses, but not of human

papillomavirus-specific cytotoxic T lymphocyte responses, after

188

peptide vaccination of patients with cervical carcinoma. J

Immunother. 23, 2000: 255-266.

184. Rintala MA, Grénman SE, Puranen MH, Isolauri E, Ekblad U,

Kero PO, Syrjänen SM. Transmission of high-risk human

papillomavirus (HPV) between parents and infant: a prospective

study of HPV in families in Finland. J Clin Microbiol. 43, 2005: 376-

381.

185. Roberts, S., Ashmole, I., Johnson, G. D., Kreider, J. W., and

Gallimore, P. H. Cutaneous and mucosal human papillomavirus E4

proteins form intermediate filament-like structures in epithelial cells.

Virology. 197, 1993: 176-187.

186. Roberts, J.N., Buck, C.B., Thompson, C.D., Kines, R. and

Bernardo, M. Genital transmission of HPV in a mouse model is

potentiated by nonoxynol-9 and inhibited by carrageenan. Nat. Med.

13, 2007: 857–861.

187. Roberts, J. N., Kines, R. C., Katki, H. A., Lowy, D. R., Schiller, J. T.

Effect of Pap Smear Collection and Carrageenan on Cervicovaginal

Human Papillomavirus-16 Infection in a Rhesus Macaque Model. J

Natl Cancer Inst. 103, 2011: 737 -743.

189

188. Rockley, P.F., and Tyring, S.K. Interferons alpha, beta and gamma

therapy of anogenital human papillomavirus infections. Pharmacol

Ther. 65, 1995: 265–287.

189. Roden, R. B., Armstrong, A., Haderer, P., Christensen, N. D.,

Hubbert, N. L., Lowy, D. R., Schiller, J. T., and Kirnbauer, R.

Characterization of a human papillomavirus type 16 variant

dependent neutralizing epitope. J Virol. 71, 1997: 6247-6252.

190. Roden, R. B., Yutzy, W. H., Fallon, R., Inglis, S., Lowy, D. R., and

Schiller, J. T. Minor capsid protein of human genital

papillomaviruses contains subdominant, cross-neutralizing epitopes.

Virology. 270, 2000: 254-257.

191. Rohlfs, M., Winkenbach, S., Meyer, S., Rupp, T., and Durst, M.

Viral transcription in human keratinocyte cell lines immortalized by

human papillomavirus type-16. Virology. 183, 1991: 331–342.

192. Rose, R. C., Bonnez, W., Reichman, R. C., and Garcea, R. L.

Expression of human papillomavirus type 11 L1 protein in insect

cells: in vivo and in vitro assembly of virus like particles. J Virol. 67,

1993: 1936-1944.

193. Rudolf, M. P., Man, S., Melief, C. J., Sette, A., and Kast, W. M.

Human T-cell responses to HLA-A-restricted high binding affinity

190

peptides of human papillomavirus type 18 proteins E6 and E7. Clin.

Cancer Res. 7, 2001: S788-S795.

194. Sachs AB, Sarnow P, Hentze MW. Starting at the beginning, middle

and end: translation initiation in eukaryotes. Cell. 89, 1997: 831-

838.

195. Salunke, D.M., Caspar, D.L.D., and Garcea, R.L. Self-assembly of

purified polyomavirus capsid protein VP1. Cell 46, 1986: 895–904.

196. Sandhu KS, Pandey S, Maiti S, Pillai B. GACCO: Genetic algorithm

simulation for codon optimization. In Silico Biol. 8, 2008: 187-192.

197. Sankaranarayanan, R., Wesley, R., Somanathan, T., Dhakad, N.,

Shyamalakumary, B., Amma, N.S., Parkin, D.M. & Nair, M.K. Visual

inspection of the uterine cervix after the application of acetic acid in

the detection of cervical carcinoma and its precursors. Cancer. 83,

1998: 2150–2156.

198. Sankaranarayanan R, Budukh A, Rajkumar R. Effective screening

programs for cervical cancer in low- and middle income developing

countries. Bull World Health Organ. 79, 2001: 954-962.

199. Sankaranarayanan R.Overview of cervical cancer in the developing

world. FIGO 26th Annual Report on the Results of Treatment in

191

Gynecological Cancer. Int J Gynaecol Obstet. 95 Suppl 1, 2006: S205-

S210.

200. Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R,

Swaminathan R, Shanthakumari S. Effect of visual screening on

cervical cancer incidence and mortality in Tamil Nadu, India: a

cluster-randomized trial. Lancet. 370, 2007: 398-406.

201. Sankaranarayanan R, Bhatla N, Gravitt PE, Basu P, Esmy PO,

Ashrafunnessa KS, Ariyaratne Y, Shah A, Nene BM. Human

papillomavirus infection and cervical cancer prevention in India,

Bangladesh, Sri Lanka and Nepal. Vaccine. 26 Suppl 12, 2008: S43-

S52.

202. Sankaranarayanan R. HPV Vaccination: the promise & problems.

Ind J Med Res. 130, 2009: 322-326.

203. Sapp, M., Fligge, C., Petzak, I., Harris, J.R., and Streeck, R.E.

Papillomavirus assembly requires trimerization of the major capsid

protein by disulfides between two highly conserved cysteines. J Virol.

72, 1998: 6186–6189.

204. Sasagawa T, Tani M, Basha W, Rose RC, Tohda H, Giga-Hama Y. A

human papillomavirus type 16 vaccine by oral delivery of L1 protein.

Virus Res. 110, 2005: 81–90.

192

205. Schirmbeck, R., Deml, L., Melber, K., Wolf, H., Wagner, R., and

Reimann, J. Priming of class I-restricted cytotoxic T lymphocytes by

vaccination with recombinant protein antigens. Vaccine. 13, 1995:

857-865.

206. Schiffman M, Castle PE. The promise of global cervical-cancer

prevention. N Engl J Med. 353, 2005: 2101-2104.

207. Schiller, J. T. and Lowy, D. R. Papillomavirus-like particles and

HPV vaccine development. Semin. Cancer Biol. 7, 1996: 373-382.

208. Schiller, J. T. Papillomavirus-like particle vaccines for cervical

cancer. Mol Med Today. 5, 1999: 209-215.

209. Schiller JT, Davies P. Delivering on the promise: HPV vaccines and

cervical cancer. Nat Rev Microbiol. 2, 2004: 343-347.

210. Schiller JT, Castellsagué X, Villa LL, Hildesheim A. An update of

prophylactic human papillomavirus L1 virus-like particle vaccine

clinical trial results. Vaccine. 26 Suppl 10, 2008: K53-K61.

211. Seedorf, K., Krammer, G., Durst, M., Suhai, S., and Rowekamp, W.

G. Human papillomavirus type 16 DNA sequence. Virology. 145,

1985: 181-185.

193

212. Sherman ME, Wang SS, Wheeler CM, Rich L, Gravitt PE, Tarone R,

Schiffman M. Determinants of human papillomavirus load among

women with histological cervical intraepithelial neoplasia 3:

dominant impact of surrounding low-grade lesions. Cancer Epidemiol

Biomarkers Prev. 12, 2003: 1038-1044.

213. Sinclair KA, Woods CR, Kirse DJ, Sinal SH. Anogenital and

respiratory tract human papillomavirus infections among children:

age, gender, and potential transmission through sexual abuse.

Pediatrics. 116, 2005: 815-825.

214. Slavinsky, J., III, Kissinger, P., Burger, L., Boley, A., DiCarlo, R.P.,

and Hagensee, M.E. Sero epidemiology of low and high oncogenic risk

types of human papillomavirus in a predominantly male cohort of

STD clinic patients. Int J STD AIDS. 12, 2001: 516–523.

215. Snijders PJ, Hogewoning CJ, Hesselink AT, Berkhof J, Voorhorst

FJ, Bleeker MC, Meijer CJ. Determination of viral load thresholds in

cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-

positive women with normal cytology. Int J Cancer. 119, 2006: 1102-

1107.

216. Sowjanya AP, Jain M, Poli UR. Prevalence and distribution of high-

risk human papillomavirus (HPV) types in invasive squamous cell

194

carcinoma of the cervix and in normal women in Andhra Pradesh,

India. BMC Infect Dis. 5, 2005: 116-122.

217. Sreekrishna K, Brankamp RG, Kropp KE, Blankenship DT, Tsay

JT, Smith PL, Wierschke JD, Subramaniam A, Birkenberger LA.

Strategies for optimal synthesis and secretion of heterologous

proteins in the methylotrophic yeast Pichia pastoris. Gene. 190,

1997: 55-62.

218. Stellato, G., Paavonen, J., Nieminen, P., Hibma, M., Vilja, P., and

Lehtinen. M. Diagnostic phase antibody response to the human

papillomavirus type 16 E2 protein is associated with successful

treatment of genital HPV lesions with systemic interferon alpha-2b.

Clin. Diagn. Virol. 7, 1997: 167–172.

219. Steller, M. Cervical cancer vaccines: progress and prospects. J Soc

Gynecol Investig. 9, 2002: 254-264.

220. Sterling, J. C., Skepper, J. N., and Stanley, M. A. Immunoelectron

microscopical localization of human papillomavirus type 16 L1 and

E4 proteins in cervical keratinocytes cultured in vivo. J Invest

Dermatol. 100, 1993: 154-158.

195

221. Stoppler, M.C., Straight, S.W., Tsao, G., Schlegel, R. & McCance,

D.J. The E5 gene of HPV-16 enhances keratinocyte immortalization

by full-length DNA. Virology. 223, 1996: 251–254.

222. Stubenrauch, F., and Laimins, L.A. Human papillomavirus life

cycle: active and latent phases. Sem. Cancer Biol. 9, 1999: 379–386.

223. Stunkel, W., Huang, Z., Tan, S.H., O’Connor, M.J., nd Bernard, H.-

U. Nuclear matrix attachment regions of human papillomavirus type

16 repress or activate the E6 promoter, depending on the physical

state of the viral DNA. J Virol. 74, 2000: 2489–2501.

224. Sudbery, P. E. The expression of recombinant proteins in yeasts.

Curr Opin Biotechnol. 7, 1996: 517-524.

225. Suzich, J.A., Ghim, S., Palmer-Hill, F.J., White, W.I., Tamura, J.K.,

Bell, J., Newsome, J.A., Jenson, A.B., and Schlegel, R. Systemic

immunization with papillomavirus L1 protein completely prevents the

development of viral mucosal papillomas. Proc. Natl. Acad. Sci. USA .

92, 1995: 11553–11557.

226. Svare, E.I., Kjaer, S.K., Nonnenmacher, B., Worm, A.M., Moi, H.,

Christensen, R.B., van den Brule, A.J., Walboomers, J.M., Meijer,

C.J., Hubbert, N.L., Lowy, D.R., and Schiller, J.T. Seroreactivity to

196

human papillomavirus type 16 virus-like particles is lower in high-

risk men than in high-risk women. J Infect Dis. 176, 1997: 876–883.

227. Tenti P, Zappatore R, Migliora P, Spinillo A, Belloni C, Carnevali L.

Perinatal transmission of human papillomavirus from gravidas with

latent infections. Obstet Gynecol. 93, 1999: 475-479.

228. Thomas, J.T., Hubert, W.G., Ruesch, M.N., and Laimins, L.A.

Human papillomavirus type 31 oncoproteins E6 and E7 are required

for the maintenance of episomes during the viral life cycle in normal

human keratinocytes. Proc. Natl. Acad. Sci. USA. 96, 1999: 8449–

8454.

229. Titolo, S., Brault, K., Majewski, J., White, P.W. & Archambault, J.

Characterization of the minimal DNA binding domain of the human

papillomavirus e1 helicase: Fluorescence anisotropy studies and

characterization of a dimerization-defective mutant protein. J Virol.

77, 2003: 5178–5191.

230. Ustav, M., and Stenlund, A. Transient replication of BPV-1

requires two viral polypeptides encoded by the E1 and E2 open

reading frames. EMBO J. 10, 1991: 449–457.

197

231. Valle, G.F. & Banks, L. The human papillomavirus (HPV)-6 and

HPV-16 E5 proteins cooperate with HPV-16 E7 in the transformation

of primary rodent cells. J gen. Virol. 76, 1995: 1239–1245.

232. van der Burg, S. H., Kwappenberg, K. M., O'Neill, T., Brandt, R. M.,

Melief, C. J., Hickling, J. K., and Offringa, R. Pre-clinical safety and

efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein

vaccine, in homologous and heterologous prime-boost regimens.

Vaccine. 19, 2001: 3652-3660.

233. Van Doornum, G.J., Prins, M., Pronk, L., Coutinho, R.A., and

Dillner, J. A prospective study of antibody responses to defined

epitopes of human papillomavirus (HPV) type 16 in relationship to

genital and ano rectal presence of HPV DNA. Clin Diagn Lab Immunol.

1, 1994: 633–639.

234. van Kuppeveld, F. J. M., de Jong, A., Dijkman, H. B. P. M., Andino,

R., and Melchers, W. J. G. Studies towards the potential of poliovirus

as a vector for the expression of HPV 16 virus-like-particles. FEMS

Immunology and Medical Microbiology. 34, 2002: 201-208.

235. Van Regenmortel, M.H.V., Fauquet, C.M., Bishop, D.H.L.,

Carstens, E.B., Estes, M.K., Lemon, S.M., Maniloff, J., Mayo, M.A.,

McGeoch, D.J., Pringle, C.R., Wickner, R.B. Virus Taxonomy: The

198

Classification and Nomenclature of viruses. The Seventh Reports of

the International Committee on Taxonomy of Viruses. Academic

press, San Diego, 2000.

236. Varsani A, Williamson AL, Rose RC, Jaffer M, Rybicki EP.

Expression of human papillomavirus type 16 major capsid protein in

transgenic Nicotiana tabacum cv. Xanthi. Arch Virol. 148, 2003: 1771-

1786.

237. Villa, L.L., Costa, R.L., Petta, C.A., Andrade, R.P., Ault, K.A.,

Giuliano, A.R., Wheeler, C.M., Koutsky, L.A., Malm, C., Lehtinen, M.,

Skjeldestad, F.E., Olsson, S.E., Steinwall, M., Brown, D.R., Kurman,

R.J., Ronnett, B.M., Stoler, M.H., Ferenczy, A., Harper, D.M., Tamms,

G.M., Yu, J., Lupinacci, L., Railkar, R., Taddeo, F.J., Jansen K.U.,

Esser, M.T., Sings, H.L., Saah, A.J., and Barr, E. Prophylactic

quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1

virus-like particle vaccine in young women: a randomized double-

blind placebo-controlled multicentre phase II efficacy trial. Lancet

Oncol. 6, 2005: 271–278.

238. Villa LL. Prophylactic HPV vaccines: reducing the burden of HPV-

related diseases. Vaccine. 24 Suppl 1, 2006: S23-S28.

199

239. Volpers, C., Schirmacher, P., Streeck, R. E., and Sapp, M.

Assembly of the major and the minor capsid protein of human

papillomavirus type 33 into virus-like particles and tubular

structures in insect cells. Virology. 200, 1994: 504-512.

240. Wank, R. and Thomssen, C. High risk of squamous cell carcinoma

of the cervix for women with HLA-DQw3. Nature. 352, 1991: 723–

725.

241. Walboomers, J. M., Jacobs, M. V., Manos, M. M., Bosch, F. X.,

Kummer, J. A., Shah, K. V., Snijders, P. J., Peto, J., Meijer, C. J.,

and Munoz, N. Human papillomavirus is a necessary cause of

invasive cervical cancer worldwide. J Pathol. 189, 1999: 12-19.

242. Wang, Z., Christensen, N., Schiller, J. T., and Dillner, J. A

monoclonal antibody against intact human papillomavirus type 16

capsids blocks the serological reactivity of most human sera. J Gen

Virol. 78, 1997: 2209-2215.

243. Wang, Z.H., Kjellberg, L., Abdalla, H., Wiklund, F., Eklund, C.,

Knekt, P., Lehtinen, M., Kallings, I., Lenner, P., Hallmans, G.,

Mahlck, C.G., Wadell, G., Schiller, J., and Dillner, J. Type specificity

and significance of different isotypes of serum antibodies to human

papillomavirus capsids. J Infect Dis. 181, 2000: 456–462.

200

244. White, A.E., Livanos, E.M., and Tlsty, T.D. Differential disruption

of genomic integrity and cell cycle regulation in normal human

fibroblasts by the HPV onco proteins. Genes Dev. 8, 1994: 666–677.

245. White, P.W., Pelletier, A., Brault, K., Titolo, S., Welchner, E.,

Thauvette, L., Fazekas, M., Cordingley, M.G. & Archambault, J.

Characterization of recombinant HPV6 and 11 E1 helicases. Effect of

ATP on the interaction of E1 with E2 and mapping of a minimal

helicase domain. J biol Chem. 276, 2001: 22426–22438.

246. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV

Information Centre). Human Papillomavirus and Related Cancers in

India. Summary Report, 2010: 6-15 (www.who.int./hpvcentre).

247. Wideroff, L., Schiffman, M.H., Nonnenmacher, B., Hubbert, N.,

Kirnbauer, R., Greer, C.E., Lowy, D., Lorincz, A.T., Manos, M.M.,

Glass, A.G., Scott, D.R., Sherman, M.E., Buckland, J., Lowy, D., and

Schiller, J. Evaluation of sero reactivity to human papillomavirus

type 16 virus-like particles in an incident case-control study of

cervical neoplasia. J Infect Dis. 172, 1995: 1425–1430.

248. Wikstrom, A., Van Doornum, G.J., Quint, W.G., Schiller, J.T., and

Dillner, J. Identification of human papillomavirus sero conversions. J

Gen Virol. 76, 1995b: 529–539.

201

249. Wilson, V. G., West, M., Woytek, K., and Rangasamy, D.

Papillomavirus E1 proteins: form, function, and features. Virus

Genes. 24, 2002: 275-290.

250. Winer RL, Kiviat NB, Hughes JP. Development and duration of

human papillomavirus lesions, after initial infection. J Infect Dis.

191, 2005: 731-738.

251. Woodworth, C.D., Lichti, U., Simpson, S., Evans, C.H., and

DiPaolo, J.A. Leukoregulin and gamma-interferon inhibit human

papillomavirus type 16 gene transcription in human papillomavirus-

immortalized human cervical cells. Cancer Res. 52, 1992: 456–463.

252. Wu, X., Xiao, W., and Brandsma, J.L. Papilloma formation by

cottontail rabbit papillomavirus requires E1 and E2 regulatory genes

in addition to E6 and E7 transforming genes. J Virol. 68, 1994: 6097–

6102.

253. Wurm, F. and Bernard, A. Large-scale transient expression in

mammalian cells for recombinant protein production. Curr Opin

Biotechnol. 10, 1999: 156-159.

254. Yang, R., Murillo, F.M., Delannoy, M.J., Blosser, R.L., Yutzy,

W.H.T., Uematsu, S., Takeda, K., Akira, S., Viscidi, R.P., and Roden,

202

R.B. B lymphocyte activation by human papillomavirus-like particles

directly induces Ig class switch recombination via TLR4-MyD88. J

Immunol. 174, 2005: 7912–7919.

255. Yim, T. J., Tang, S., and Andino, R. Poliovirus recombinants

expressing hepatitis B virus antigens elicited a humoral immune

response in susceptible mice. Virology. 218, 1996: 61-70.

256. Yufang Hu, Roya Zandi, Adriana Anavitarte, Charles M. Knobler,

William M. Gelbart. Packaging of a Polymer by a Viral Capsid: The

Interplay between Polymer Length and Capsid Size. Biophys J. 94,

2008: 1428–1436.

257. Yutsudo, M., Okamoto, Y., and Hakura, A. Functional dissociation

of transforming genes of human papillomavirus type 16. Virology.

166, 1988: 594–597.

258. Zinkernagel, R.M. On natural and artificial vaccinations. Ann Rev

Immunol. 21, 2003: 515–546.

259. Zhang, B., Spandau, D.F. & Roman, A. E5 protein of human

papillomavirus type 16 protects human foreskin keratinocytes from

UV B-irradiation-induced apoptosis. J Virol. 76, 2002: 220–231.

203

260. Zou, N., Lin, B.Y., Duan, F., Lee, K.-Y., Jin, G., Guan, R., Yao, G.,

Lefkowitz, E.J., Broker, T.R. & Chow, L.T. The hinge of the human

papillomavirus type 11 E2 protein contains major determinants for

nuclear localization and nuclear matrix association. J Virol. 74, 2000:

3761–3770.

261. Zhou, J., Doorbar, J., Sun, X. Y., Crawford, L. V., McLean, C. S.,

and Frazer, I. H. Identification of the nuclear localization signal of

human papilloma virus type 16 L1 protein. Virology. 185, 1991a:

625-632.

262. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia

recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is

sufficient for assembly of HPV virion-like particles. Virology. 185,

1991b: 251-257.

263. Zhou, J., Stenzel, D.J., Sun, X.Y., and Frazer, I.H. Synthesis and

assembly of infectious bovine papilloma virus particles in vitro. J Gen

Virol. 74, 1993: 763–768.

264. zur Hausen H. Papillomavirus infections--a major cause of human

cancers. Biochem Biophys Acta. 1288, 1996: F55-F78.

265. zur Hausen, H. Papillomaviruses and cancer: From basic studies to

clinical application. Nat Rev Cancer. 2, 2002: 342–350.